Project UpdateJul 27, 2026, 04:07 PM
Veraxa Biotech Advances Bispecific ADC Program VXA-222
AI Summary
Veraxa Biotech AG announced the advancement of its novel bispecific antibody drug conjugate (bsADC) program VXA-222. This follows the successful achievement of a key technical milestone in its alliance with OmniAb, Inc., with OmniAb's discovery work now concluded. VXA-222 employs an "AND-gate" logic to address two different target antigens present on solid tumors, representing a significant step in developing next-generation cancer therapies.
Key Highlights
- Veraxa Biotech announced the advancement of its bispecific ADC program VXA-222.
- The program achieved a key technical milestone in its alliance with OmniAb.
- OmniAb's discovery work for VXA-222 has been successfully concluded.
- VXA-222 utilizes an "AND-gate" logic to target two antigens on solid tumors.
- The alliance with OmniAb was established in May 2025.
- Veraxa holds exclusive rights to develop and commercialize products from the collaboration.
- OmniAb is entitled to a share of specified revenue generated from these products.
Price Impact
More from VRXA